EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

WuYeLuGen Granule Attenuates Bleomycin‐Induced Pulmonary Fibrosis in Rats by Inhibiting the TGF‐β1/Smad Signaling Pathway and Epithelial–Mesenchymal Transition

Jia-Wei Zeng iD, Li Lin iD, Yan-Jun Duan iD

Canadian Respiratory Journal · 2026-01 · 2026 (1)

DOI: 10.1155/carj/8103859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Respiratory Journal, online erschienen am 23.02.2026. Verfasst von Jia-Wei Zeng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, College of Basic Medical Sciences, Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan, 430065, China, hb…. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Drugs, Chinese Herbal, Pulmonary Fibrosis, Epithelial-Mesenchymal Transition. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary fibrosis is a chronic disease characterized by progressive interstitial lung changes affecting alveolar epithelial cells and pulmonary vessels. Following COVID‐19, it has emerged as a significant sequela in severe cases, often with a poor prognosis. WuYeLuGen (WYLG) Granule, derived by Xue’s Wuye Lugen Granule, exerts effects of replenishing qi, nourishing yin, clearing heat, and resolving dampness. While clinical and experimental studies provide evidence to support WYLG’s efficacy against early‐stage pulmonary fibrosis, its underlying mechanisms remain incompletely understood.

Methods

Active components of WYLG were identified using LC‐MS/MS. CCK8 assays were performed to determine the optimal concentrations of WYLG‐containing serum and TGF‐β1. WYLG granules were administered to bleomycin (BLM)‐induced rats and WYLG‐containing serum was applied to TGF‐β1‐stimulated rat pulmonary fibroblasts (RPFs). Hematoxylin‐Eosin (HE) and Masson staining were used to assess the protective effects of WYLG on rat lung tissues, while enzyme‐linked immunosorbent assay (ELISA) was employed to evaluate lung inflammation. Flow cytometry analyzed RPF cell proliferation, scratch assays examined cell migration, and Western blot detected the expression of fibrotic and pathway‐related proteins. Immunofluorescence was used to confirm the efficacy of WYLG in reducing RPF cell fibrosis.

Results

LC‐MS/MS identified 18 active components in WYLG, primarily derived from Salvia miltiorrhiza and Astragalus membranaceus . The optimal concentration for TGF‐β1‐induced RPF stimulation was 10 ng/mL, and the optimal concentration of WYLG‐containing serum was 10%. In BLM‐induced rats, WYLG granules significantly alleviated pulmonary fibrosis, reduced inflammatory cell infiltration and collagen deposition, downregulated IL‐6 and α‐SMA levels, and upregulated E‐cadherin expression. Mechanistically, WYLG treatment decreased the levels of TGF‐β1 and p‐Smad2/Smad2, while increasing Smad7 levels in rat lung tissue. In TGF‐β1‐stimulated RPF, WYLG‐containing serum normalized cell proliferation, inhibited cell migration, reduced collagen I and α‐SMA expression, and increased E‐cadherin expression. Consistent with animal experiments, WYLG‐containing serum also downregulated TGF‐β1 and p‐Smad2/Smad2 levels in RPFs. Additionally, the TGF‐β1/Smad pathway agonist SRI‐011381 reversed the inhibitory effects of WYLG on RPF fibrosis, further confirming that WYLG exerts its antifibrotic effect through the TGF‐β1/Smad pathway.

Conclusions

WYLG markedly alleviates pulmonary fibrosis both in vivo and in vitro by inhibiting the TGF‐β1/Smad signaling pathway and regulating epithelial‐to‐mesenchymal transition, highlighting its potential as a therapeutic agent for progressive pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor beta1Drugs, Chinese HerbalPulmonary FibrosisEpithelial-Mesenchymal TransitionSmad ProteinsAnimalsRatsSignal TransductionBleomycinMaleRats, Sprague-DawleyDisease Models, AnimalLungFibroblastsCell ProliferationCell Movement

Stichwörter der Autor:innen

TGF-β1/Smad pathwayWuYeLuGen Granuleepithelial–mesenchymal transitionpulmonary fibrosis

Substanzen

Transforming Growth Factor beta1Drugs, Chinese HerbalBleomycinSmad Proteins

Autor:innen und Institutionen

  • Department of Physiology, College of Basic Medical Sciences, Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan, 430065, China, hbtcm.edu.cn.
  • Department of Anatomy Teaching and Research, College of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, 430065, China, hbtcm.edu.cn.

ORCID-Profile: Jia-Wei Zeng, Li Lin, Yan-Jun Duan

Zitieren

APA

Zeng, J. W., Lin, L., & Duan, Y. J. (2026). WuYeLuGen Granule Attenuates Bleomycin‐Induced Pulmonary Fibrosis in Rats by Inhibiting the TGF‐β1/Smad Signaling Pathway and Epithelial–Mesenchymal Transition. Canadian Respiratory Journal, 2026(1). https://doi.org/10.1155/carj/8103859

Vancouver

Zeng JW, Lin L, Duan YJ. WuYeLuGen Granule Attenuates Bleomycin‐Induced Pulmonary Fibrosis in Rats by Inhibiting the TGF‐β1/Smad Signaling Pathway and Epithelial–Mesenchymal Transition. Canadian Respiratory Journal. 2026;2026(1). doi:10.1155/carj/8103859

BibTeX
@article{Zeng2026,
  author = {Zeng, Jia-Wei and Lin, Li and Duan, Yan-Jun},
  title = {WuYeLuGen Granule Attenuates Bleomycin‐Induced Pulmonary Fibrosis in Rats by Inhibiting the TGF‐β1/Smad Signaling Pathway and Epithelial–Mesenchymal Transition},
  journal = {Canadian Respiratory Journal},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/carj/8103859}
}
Kostenlos starten →